Stämm's Continuous Bioreactor Increases Antibody Productivity by up to 30x in European and American Pilots
January 15, 2025 | 02:56
Pilot runs in Europe and South America show breakthrough efficiency in monoclonal antibody production with unprecedented cost savings and scalability using Stämm's bubble-free continuous laminar flow bioreactor: the Bioprocessor.
Mobile Version